【Description】
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for PARP (Poly ADP-Ribose Polymerase) Inhibitor was estimated at US$ 5138.9 million in the year 2022, is projected to reach a revised size of US$ 8571.2 million by 2029, growing at a CAGR of 8.9% during the forecast period 2023-2029.
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%.
North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent.
In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.
Report Scope
This report aims to provide a comprehensive presentation of the global market for PARP (Poly ADP-Ribose Polymerase) Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PARP (Poly ADP-Ribose Polymerase) Inhibitor.
The PARP (Poly ADP-Ribose Polymerase) Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
Market Segmentation
This report covers the PARP (Poly ADP-Ribose Polymerase) Inhibitor segments by manufacturers, by type, by application, by region and country, and provides market size (value, volume and average price) and CAGR for the history and forecast period (2018-2023, 2024-2029), considering 2022 as the base year. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
By Company
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
GSK
Zai Lab
Segment by Type
Lynparza
Zejula
Rubraca
Talzenna
Other
Segment by Application
Ovarian Cancer
Breast Cancer
Other
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter Two: Detailed analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger and acquisition information, etc.
Chapter Three: Sales, revenue of PARP (Poly ADP-Ribose Polymerase) Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
【Table of Contents】
1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Overview
1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Overview
1.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segment by Type
1.2.1 Lynparza
1.2.2 Zejula
1.2.3 Rubraca
1.2.4 Talzenna
1.2.5 Other
1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Type
1.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Overview by Type (2018-2029)
1.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Historic Market Size Review by Type (2018-2023)
1.3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2018-2023)
1.4.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2018-2023)
1.4.4 I194 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2018-2023)
2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Competition by Company
2.1 Global Top Players by PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (2018-2023)
2.2 Global Top Players by PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2018-2023)
2.3 Global Top Players by PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (2018-2023)
2.4 Global Top Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base Distribution, Sales Area, Product Type
2.5 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Competitive Situation and Trends
2.5.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in PARP (Poly ADP-Ribose Polymerase) Inhibitor as of 2022)
2.7 Date of Key Manufacturers Enter into PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
2.8 Key Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
2.9 Mergers & Acquisitions, Expansion
3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Status and Outlook by Region
3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Historic Market Size by Region
3.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Region (2018-2023)
3.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Region (2018-2023)
3.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecasted Market Size by Region
3.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Region (2024-2029)
3.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Region (2024-2029)
3.3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor by Application
4.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segment by Application
4.1.1 Ovarian Cancer
4.1.2 Breast Cancer
4.1.3 Other
4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Application
4.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Overview by Application (2018-2029)
4.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Historic Market Size Review by Application (2018-2023)
4.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Application (2018-2023)
4.3.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Application (2018-2023)
4.3.4 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Application (2018-2023)
5 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
5.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Historic Market Size by Country
5.1.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2018-2023)
5.1.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Country (2018-2023)
5.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecasted Market Size by Country
5.2.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2024-2029)
5.2.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Country (2024-2029)
6 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
6.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Historic Market Size by Country
6.1.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2018-2023)
6.1.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Country (2018-2023)
6.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecasted Market Size by Country
6.2.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2024-2029)
6.2.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Country (2024-2029)
7 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor by Region
7.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Historic Market Size by Region
7.1.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Region (2018-2023)
7.2 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecasted Market Size by Region
7.2.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Region (2024-2029)
8 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
8.1 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Historic Market Size by Country
8.1.1 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2018-2023)
8.1.3 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Country (2018-2023)
8.2 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecasted Market Size by Country
8.2.1 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2024-2029)
8.2.2 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Country (2024-2029)
9 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
9.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Historic Market Size by Country
9.1.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Country (2018-2023)
9.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecasted Market Size by Country
9.2.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 AstraZeneca
10.1.1 AstraZeneca Company Information
10.1.2 AstraZeneca Introduction and Business Overview
10.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.1.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
10.1.5 AstraZeneca Recent Development
10.2 Tesaro
10.2.1 Tesaro Company Information
10.2.2 Tesaro Introduction and Business Overview
10.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
10.2.5 Tesaro Recent Development
10.3 Merck & Co
10.3.1 Merck & Co Company Information
10.3.2 Merck & Co Introduction and Business Overview
10.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
10.3.5 Merck & Co Recent Development
10.4 Clovis Oncology
10.4.1 Clovis Oncology Company Information
10.4.2 Clovis Oncology Introduction and Business Overview
10.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
10.4.5 Clovis Oncology Recent Development
10.5 Pfizer
10.5.1 Pfizer Company Information
10.5.2 Pfizer Introduction and Business Overview
10.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
10.5.5 Pfizer Recent Development
10.6 GSK
10.6.1 GSK Company Information
10.6.2 GSK Introduction and Business Overview
10.6.3 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.6.4 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
10.6.5 GSK Recent Development
10.7 Zai Lab
10.7.1 Zai Lab Company Information
10.7.2 Zai Lab Introduction and Business Overview
10.7.3 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
10.7.5 Zai Lab Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industrial Chain Analysis
11.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Dynamics
11.4.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Trends
11.4.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Drivers
11.4.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Challenges
11.4.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors
12.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
【Table of Figures】
List of Tables
Table 1. Major Company of Lynparza
Table 2. Major Company of Zejula
Table 3. Major Company of Rubraca
Table 4. Major Company of Talzenna
Table 5. Major Company of Other
Table 6. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2018-2023) & (K Units)
Table 8. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Type (2018-2023)
Table 9. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2018-2023) & (US& Million)
Table 10. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share in Value by Type (2018-2023)
Table 11. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2018-2023) & (USD/Unit)
Table 12. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2024-2029) & (K Units)
Table 13. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Type (2024-2029)
Table 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2024-2029) & (US$ Million)
Table 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Type (2024-2029)
Table 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2024-2029) & (USD/Unit)
Table 17. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2018-2023) & (K Units)
Table 18. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2018-2023) & (US$ Million)
Table 19. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Type (2018-2023)
Table 20. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2018-2023) & (US$ Million)
Table 21. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Type (2018-2023)
Table 22. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2018-2023) & (US$ Million)
Table 23. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Type (2018-2023)
Table 24. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2018-2023) & (US$ Million)
Table 25. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Type (2018-2023)
Table 26. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2018-2023) & (US$ Million)
Table 27. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Company (2018-2023) & (K Units)
Table 28. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Company (2018-2023)
Table 29. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2018-2023) & (US$ Million)
Table 30. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Company (2018-2023)
Table 31. Global Market PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Company (2018-2023) & (USD/Unit)
Table 32. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 33. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 34. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in PARP (Poly ADP-Ribose Polymerase) Inhibitor as of 2022)
Table 35. Date of Key Manufacturers Enter into PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
Table 36. Key Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Type
Table 37. Mergers & Acquisitions, Expansion Plans
Table 38. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 39. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2018-2023) & (K Units)
Table 40. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Region (2018-2023)
Table 41. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2018-2023) & (US$ Million)
Table 42. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Region (2018-2023)
Table 43. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 44. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2024-2029) & (K Units)
Table 45. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Region (2024-2029)
Table 46. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2024-2029) & (US$ Million)
Table 47. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Region (2024-2029)
Table 48. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2024-2029)
Table 49. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 50. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2023) & (K Units)
Table 51. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Application (2018-2023)
Table 52. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2023) & (US$ Million)
Table 53. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Application (2018-2023)
Table 54. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2018-2023) & (USD/Unit)
Table 55. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2024-2029) & (K Units)
Table 56. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Application (2024-2029)
Table 57. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2024-2029) & (US$ Million)
Table 58. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Application (2024-2029)
Table 59. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2024-2029) & (USD/Unit)
Table 60. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2023) (K Units)
Table 61. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2023) & (US$ Million)
Table 62. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2023) (K Units)
Table 63. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2023) & (US$ Million)
Table 64. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2023) (K Units)
Table 65. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2023) & (US$ Million)
Table 66. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2023) (K Units)
Table 67. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2023) & (US$ Million)
Table 68. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2023) (K Units)
Table 69. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2023) & (US$ Million)
Table 70. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2018-2023) & (K Units)
Table 71. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Country (2018-2023)
Table 72. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2018-2023) & (US$ Million)
Table 73. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Country (2018-2023)
Table 74. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2024-2029) & (K Units)
Table 75. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Country (2024-2029)
Table 76. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2024-2029) & (US$ Million)
Table 77. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Country (2024-2029)
Table 78. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2018-2023) & (K Units)
Table 79. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Country (2018-2023)
Table 80. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2018-2023) & (US$ Million)
Table 81. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Country (2018-2023)
Table 82. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2024-2029) & (K Units)
Table 83. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Country (2024-2029)
Table 84. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2024-2029) & (US$ Million)
Table 85. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Country (2024-2029)
Table 86. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2018-2023) & (K Units)
Table 87. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Region (2018-2023)
Table 88. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2018-2023) & (US$ Million)
Table 89. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Region (2018-2023)
Table 90. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2024-2029) & (K Units)
Table 91. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Region (2024-2029)
Table 92. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2024-2029) & (US$ Million)
Table 93. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Region (2024-2029)
Table 94. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2018-2023) & (K Units)
Table 95. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Country (2018-2023)
Table 96. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2018-2023) & (US$ Million)
Table 97. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Country (2018-2023)
Table 98. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2024-2029) & (K Units)
Table 99. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Country (2024-2029)
Table 100. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2024-2029) & (US$ Million)
Table 101. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Country (2024-2029)
Table 102. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2018-2023) & (K Units)
Table 103. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Country (2018-2023)
Table 104. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2018-2023) & (US$ Million)
Table 105. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Country (2018-2023)
Table 106. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2024-2029) & (K Units)
Table 107. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Country (2024-2029)
Table 108. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2024-2029) & (US$ Million)
Table 109. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Country (2024-2029)
Table 110. AstraZeneca Company Information
Table 111. AstraZeneca Introduction and Business Overview
Table 112. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 113. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 114. AstraZeneca Recent Development
Table 115. Tesaro Company Information
Table 116. Tesaro Introduction and Business Overview
Table 117. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 118. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 119. Tesaro Recent Development
Table 120. Merck & Co Company Information
Table 121. Merck & Co Introduction and Business Overview
Table 122. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 123. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 124. Merck & Co Recent Development
Table 125. Clovis Oncology Company Information
Table 126. Clovis Oncology Introduction and Business Overview
Table 127. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 128. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 129. Clovis Oncology Recent Development
Table 130. Pfizer Company Information
Table 131. Pfizer Introduction and Business Overview
Table 132. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 133. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 134. Pfizer Recent Development
Table 135. GSK Company Information
Table 136. GSK Introduction and Business Overview
Table 137. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 138. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 139. GSK Recent Development
Table 140. Zai Lab Company Information
Table 141. Zai Lab Introduction and Business Overview
Table 142. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 143. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 144. Zai Lab Recent Development
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Trends
Table 148. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Drivers
Table 149. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Challenges
Table 150. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Restraints
Table 151. PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors List
Table 152. PARP (Poly ADP-Ribose Polymerase) Inhibitor Downstream Customers
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Picture
Figure 2. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Status and Outlook (2018-2029) & (K Units)
Figure 5. Product Picture of Lynparza
Figure 6. Global Lynparza Sales YoY Growth (2018-2029) & (K Units)
Figure 7. Product Picture of Zejula
Figure 8. Global Zejula Sales YoY Growth (2018-2029) & (K Units)
Figure 9. Product Picture of Rubraca
Figure 10. Global Rubraca Sales YoY Growth (2018-2029) & (K Units)
Figure 11. Product Picture of Talzenna
Figure 12. Global Talzenna Sales YoY Growth (2018-2029) & (K Units)
Figure 13. Product Picture of Other
Figure 14. Global Other Sales YoY Growth (2018-2029) & (K Units)
Figure 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2018-2029) & (US$ Million)
Figure 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type in 2022 & 2029
Figure 17. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Type in 2022
Figure 18. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Type in 2022
Figure 19. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Type in 2022
Figure 20. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Type in 2022
Figure 21. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Type in 2022
Figure 22. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Type in 2022
Figure 23. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Type in 2022
Figure 24. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Type in 2022
Figure 25. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Type in 2022
Figure 26. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Type in 2022
Figure 27. The 5 and 10 Largest Manufacturers in the World: Market Share by PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in 2022
Figure 28. The 5 and 10 Largest Manufacturers in the World: Market Share by PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue in 2022
Figure 29. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Product Picture of Ovarian Cancer
Figure 31. Global Ovarian Cancer Sales YoY Growth (2018-2029) & (K Units)
Figure 32. Product Picture of Breast Cancer
Figure 33. Global Breast Cancer Sales YoY Growth (2018-2029) & (K Units)
Figure 34. Product Picture of Other
Figure 35. Global Other Sales YoY Growth (2018-2029) & (K Units)
Figure 36. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2029) & (US$ Million)
Figure 37. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application in 2022 & 2029
Figure 38. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Application in 2022
Figure 39. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Application in 2022
Figure 40. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Application in 2022
Figure 41. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Application in 2022
Figure 42. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Application in 2022
Figure 43. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Application in 2022
Figure 44. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Volume by Application in 2022
Figure 45. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Application in 2022
Figure 46. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share in Value by Application in 2022
Figure 47. Key Raw Materials Price
Figure 48. PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Cost Structure
Figure 49. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industrial Chain Analysis
Figure 50. Channels of Distribution
Figure 51. Distributors Profiles
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed